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Summary
Background.  —  It  is  unknown  whether  the  efﬁcacy  and  safety  of  drug-eluting  stents  (DES)  apply
in patients  with  chronic  renal  failure  (CRF).
Aims.  —  To  compare  DES  with  bare  metal  stents  (BMS)  for  percutaneous  coronary  intervention
(PCI) in  CRF  patients.
Patients  and  methods.  —  Consecutive  patients  treated  by  PCI  were  allocated  to  four  groups
according  to  type  of  stent  used  (DES  versus  BMS)  and  creatinine  clearance  (CrCl).  CRF  was
deﬁned as  CrCl  less  than  60  mL/minute.  Cardiovascular  death,  major  adverse  cardiac  events
(MACE, deﬁned  as  cardiovascular  death,  myocardial  infarction,  stroke  and  target  lesion  revas-
cularization  [TLR]),  TLR  and  deﬁnite  stent  thrombosis  (ST)  were  recorded  at  1  year.
Results. —  We  note  that  1376  consecutive  patients  underwent  PCI  with  stent  within  18  months:
534 (39%)  and  492  (36%)  patients  without  CRF  and  224  (16%)  and  126  (9%)  patients  with  CRFES,  respectively.  In  the  entire  cohort,  patients  treated  with  DES  hadwere treated  with  BMS  and  D
a higher  restenosis  risk  proﬁle.  BMS  were  predominantly  (87%)  used  for  ST-segment  elevation
myocardial  infarction.  At  1  year,  6.2%  had  cardiovascular  death,  15.8%  MACE,  7.3%  TLR  and  1.5%
ST. Cardiovascular  death  and  MACE  occurred  less  frequently  in  DES  groups.  The  TLR  rate  was
not signiﬁcantly  different  in  the  CRF  groups  (BMS  9.8%  vs  DES  7.1%;  P  =  0.44).  No  excess  of  ST
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was  observed  in  the  DES  groups  and  use  of  DES  was  independently  associated  with  absence  of
MACE and  TLR.
Conclusions.  —  In  patients  with  CRF,  DES  appear  to  be  at  least  as  effective  as  BMS  —– despite  a
higher restenosis  risk  proﬁle  —– with  no  excess  of  ST  at  1  year.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Context.  — Peu  de  données  sont  disponibles  sur  l’efﬁcacité  et  la  sécurité  des  stents  actifs  (DES)
chez les  patients  avec  insufﬁsance  rénale  (CRF).
Objectif  Comparer  DES  et  stents  nus  (BMS)  lors  de  l’angioplastie  coronaire  (PCI)  chez  les
patients avec  CRF.
Patients  et  méthodes.  —  Une  série  consécutive  de  patients  traités  par  PCI  ont  été  répartis  en
quatre groupes  selon  le  stent  utilisé  (DES  ou  BMS),  et  la  clairance  de  la  créatinine  (CrCl).  CRF
était déﬁni  par  une  CrCl  inférieure  à  60  mL/min.  Les  décès  cardiovasculaire  (CV),  revasculari-
sation de  la  lésion  cible  (TLR),  thrombose  certaine  de  stent  (ST),  événement  cardiaque  majeur
(MACE) incluant  décès  CV,  infarctus,  accident  vasculaire  cérébral  et  TLR  ont  été  analysés  à  un
an.
Résultats.  — On  note  que  1376  patients  consécutifs  ont  été  traités  par  PCI  en  18  mois  :  534  (39  %),
492 (36  %),  224  (16  %)  et  126  (9  %)  patients  ont  été  répartis  dans  les  groupes  BMS,  DES,  BMS  CRF
et DES  CRF.  Les  patients  traités  par  DES  avaient  un  plus  haut  risque  de  resténose.  Le  BMS  était
préférentiellement  utilisé  en  phase  aiguë  d’infarctus.  À  un  an,  le  taux  de  décès  CV  était  de
6,2 %,  avec  15,8  %  de  MACE,  7,3  %  de  TLR  et  1,1  %  de  ST.  Les  décès  CV  et  MACE  étaient  moins
fréquents  dans  les  groupes  avec  DES.  Dans  le  groupe  avec  CRF,  le  taux  de  TLR  était  comparable
avec BMS  et  DES  (9,8  %  vs  7,1  %  ;  p  =  0,44).  Il  n’a  pas  été  observé  d’excès  de  ST  avec  le  DES,  et
l’utilisation  de  DES  était  associée  de  manière  indépendante  à  un  moindre  risque  de  MACE  et  TLR.
Conclusion.  —  Chez  les  patients  avec  CRF,  le  DES  apparaît  au  moins  aussi  efﬁcace  que  le  BMS,
malgré un  proﬁl  plus  à  risque  de  resténose,  sans  excès  de  ST  à  un  an.
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Background
Patients  with  chronic  renal  failure  (CRF)  carry  the  risk  of
severe  coronary  artery  disease,  with  cardiovascular  death
accounting  for  almost  50%  of  the  total  mortality  in  this  popu-
lation  [1,2]. Outcomes  after  percutaneous  coronary  inter-
vention  (PCI)  —– with  balloon  or  bare  metal  stents  (BMS)  —–
remain  poor  compared  with  in  patients  with  normal  renal
function  [1,3], with  no  prognostic  beneﬁt  demonstrated  with
this  revascularization  strategy  [4].  Some  authors  report  an
increased  rate  of  silent  in-stent  restenosis  in  CRF  patients,
which  could  partly  explain  these  adverse  outcomes  [1].
Drug-eluting  stents  (DES)  dramatically  decrease  the  rates
of  in-stent  restenosis  and  subsequent  target  lesion  reva-
scularization  (TLR)  compared  with  BMS  in  the  general  popu-
lation  [5,6]. However,  little  is  known  about  the  subset  of
patients  with  CRF.
The  purpose  of  the  present  study  was  to  assess  the  efﬁ-
cacy  and  safety  of  DES  (vs  BMS)  in  the  contemporary  practice
of  PCI  (elective  or  urgent)  in  a  consecutive,  non-selected
population  of  patients  with  CRF.
Patients and methods
Patient populationAll  patients  treated  by  PCI  with  at  least  one  stent  in  our
institution  were  included  between  August  2007  and  January
2009.  This  was  an  ‘‘all-comers’’,  prospective,  single-centre
registry.  Patients  treated  by  balloon  angioplasty  without
P
P
ts  droits  réservés.
ubsequent  stent  implantation  (n  =  68)  were  excluded.  Dur-
ng  the  1-year  follow-up  period,  new  PCIs  were  counted  as
utcomes  (n  =  124).  Clinical  and  angiographical  data  were
rospectively  entered  into  the  web-based  ‘‘Middle  Care’’
atabase.
Aspirin  and  clopidogrel  pretreatment  or  loading  dose  (300
o  900  mg)  was  given  before  PCI.  Periprocedural  0.9%  saline
ntravenous  perfusion  (100  mL/hour)  was  achieved  12  hours
efore  and  after  PCI,  except  in  patients  with  congestive
eart  failure.  All  patients  —– except  those  previously  treated
y  vitamin  K  antagonists  —– received  intravenous  low  mole-
ular  weight  heparin  during  PCI.  The  use  of  glycoprotein
Ib/IIIa  inhibitors  was  left  to  the  operators’  discretion;  they
ere  mostly  used  in  cases  of  primary  PCI  for  ongoing  stent
hrombosis  (ST)-segment  elevation  myocardial  infarction,  in
igh-risk  acute  coronary  syndrome  patients  or  in  bail-out
ituations.  PCI  was  performed  according  to  standard  guide-
ines,  mostly  by  the  radial  approach,  using  ﬁve  or  six  French
heaths  with  systematic  stent  implantation  (unless  inappro-
riate).  The  usual  aspirin  maintenance  dose  was  75  mg/day
hile  the  daily  clopidogrel  dose  was  75  to  150  mg.  Dual
ntiplatelet  therapy  was  maintained  for  12  months  in  cases
f  acute  coronary  syndrome  or  DES  implantation  and  could
e  switched  to  single  antithrombotic  therapy  after  1  month
n  cases  of  BMS  implantation  in  a  non-urgent  setting.atient assessments
atients  were  allocated  to  four  patient  groups  according  to
he  stent  used  (BMS  versus  DES)  and  renal  function  (CRF
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60  mL/minute;12.8%  and  25.5%  in  patients  with  30  mL/minute
≤  CrCl  <  60  mL/minute;  20.3%  and  28.8%  in  patients  with
CrCl  <  30  mL/minute,  respectively).  Deﬁnite  ST  occurred  in
2.8%  (n  =  15)  of  the  NO  CRF-BMS  group,  0.4%  (n  =  1)  of  the  NO06  
s  NO  CRF).  Chronic  renal  failure  was  deﬁned  as  creatinine
learance  (CrCl)  less  than  60  mL/minute  calculated  with  the
ockroft  formula.  Patients  treated  with  both  DES  and  BMS
ere  allocated  to  the  DES  groups.
Death  was  deﬁned  as  death  from  any  cause.  Cardiovascu-
ar  death  was  deﬁned  as  death  from  cardiovascular  cause  or
udden  death  without  extracardiovascular  cause.  Myocardial
nfarction  was  deﬁned  as  recurrent  chest  pain  and/or  elec-
rocardiogram  changes  with  at  least  one  of  the  following
riteria:  creatine  kinase  and  troponin  I  ≥  2  times  the  upper
imit  of  normal  with  an  increase  of  more  than  50%  of  the
rior  value;  and  the  appearance  of  a  new  left  bundle-branch
lock  or  new  Q  waves.  Stroke  was  deﬁned  as  an  acute  neu-
ological  deﬁcit  lasting  for  more  than  24  hours,  classiﬁed
y  neurological  evaluation.  Clinical  TLR  was  deﬁned  as  new
evascularization  of  the  treated  lesion  mandated  by  clinical
ymptoms  or  documented  ischaemia.  Major  adverse  cardiac
vents  (MACE)  were  deﬁned  as  the  composite  of  cardiovas-
ular  death,  myocardial  infarction,  stroke  and  TLR.  Stent
hrombosis  (ST)  was  deﬁned  as  deﬁnite  ST  according  to  the
merican  Research  Consortium  criteria  [7].
ardiovascular events
he  primary  endpoint  was  the  rate  of  MACE  and  the  secon-
ary  endpoint  was  the  rate  of  TLR  at  1  year.  The  safety  end-
oint  was  the  rate  of  ST  at  1  year.  One-year  clinical  outcomes
ere  obtained  by  medical  consultation,  from  the  rehospital-
zation  medical  report  or  by  telephone  call.
tatistical analyses
ategorical  variables  are  expressed  as  numbers  and
ercentages  (%);  continuous  variables  are  expressed  as
eans  ±  standard  deviations.  Univariate  analyses  were  per-
ormed  using  the  chi-square  test  for  categorical  variables
nd  Student’s  t test  for  continuous  variables.  Kaplan-Meier
urves  were  drawn  using  GraphPad  Prism  (version  5.01  for
indows;  GraphPad  Software,  San  Diego,  CA,  USA).  Multi-
ariable  analyses  were  performed  using  a  multiple  logistic
egression  model.  The  statistical  analyses  were  performed
ith  Statview  software  (version  5.0;  SAS  Institute  Inc.,  Cary,
C,  USA).
esults
aseline characteristics
mong  the  1376  consecutive  patients  who  underwent  PCI
ith  stent  implantation  in  our  institution,  534  (39%),  492
36%),  224  (16%)  and  126  (9%)  patients  were  allocated  to
he  NO  CRF-BMS,  NO  CRF-DES,  CRF-BMS  and  CRF-DES  groups,
espectively.
Baseline  clinical  and  procedural  characteristics  according
o  renal  function  and  stent  type  are  shown  in  Table  1.
hronic  renal  failure  patients  versus  NO  chronic
enal failure  patients
mong  the  350  patients  with  renal  dysfunction,  63  (18%)
ad  severe  renal  failure  (CrCl  <  30  mL/minute)  and  38  (11%)
ere  on  dialysis.  More  frequently,  patients  with  CRF  were
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lder,  were  women  and  had  a lower  body  mass  index,  more
ypertension  and  more  prior  stroke  but  were  less  likely  to
e  current  smokers  or  to  have  a  family  history  of  coro-
ary  artery  disease.  Patients  underwent  PCI  mostly  for  acute
oronary  syndrome  (n  =  728)  but  patients  with  CRF  were
ore  likely  to  be  in  cardiogenic  shock  or  out-of-hospital
ardiac  arrest  at  entrance.
The  radial  artery  was  the  main  access  for  PCI  (n  =  1087),
lthough  radial  PCI  was  used  slightly  less  frequently  in
atients  with  CRF.  Patients  with  CRF  had  multivessel  dis-
ase  more  frequently,  with  stenosis  more  often  located  on
he  left  main  or  left  anterior  descending  artery.  The  num-
er,  length  and  diameter  of  stents  (per  patient)  were  not
igniﬁcantly  different,  whatever  the  renal  function.
hronic  renal  failure  subgroups
RF  patients  treated  with  DES  had  twice  more  history  of  PCI
nd  were  rarely  treated  for  acute  myocardial  infarction  or
ardiogenic  shock  compared  with  those  treated  with  BMS.
n  this  CRF  subset,  the  average  stent  diameter  was  signiﬁ-
antly  lower  in  DES  patients  versus  BMS  patients  and  the
tent  length  was  greater,  although  not  signiﬁcantly.
ne-year outcomes
ne-year  outcomes  are  shown  in  Fig.  1.  Follow-up  was
ompleted  for  1338  patients  (97.2%)  at  1  year.  During  that
eriod,  118  (8.6%)  patients  died,  85  (6.2%)  from  a  cardio-
ascular  cause,  218  (15.8%)  had  MACE  and  101  (7.3%)  had
LR.  Deﬁnite  ST  occurred  in  20  (1.5%),  probable  ST  in  four
0.5%)  and  possible  ST  in  12  (0.9%)  patients.
hronic  renal  failure  patients  versus  NO  chronic
enal failure  patients
atients  with  CRF  had  an  increased  risk  of  cardiovascu-
ar  death  and  MACE  at  1  year,  with  a  stepwise  increase
ccording  to  CrCl  (3.4%  and  12.3%  in  patients  with  CrCl  ≥igure 1. Event rates according to renal function and stent
ype (unadjusted). BMS: bare metal stent; CV: cardiovascular; DES:
rug-eluting stent; MACE: major adverse cardiac events; ST: stent
hrombosis; TLR: target lesion revascularization.
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Table  1  Baseline  clinical  and  procedural  characteristics  according  to  renal  function  and  the  type  of  stent  (n  =  1376).
CRF-BMS
(n  =  224;  16%)
CRF-DES
(n =  126;  9%)
NO  CRF-BMS
(n =  534;  39%)
NO  CRF-DES
(n =  492;  36%)
P
Age  (years)  75  ±  11  72  ±  11  62  ±  12  61  ±  11  <  0.0001
Women  76  (34)  39  (31)  93  (17)  77  (16)  <  0.0001
BMI 25  ±  4  24  ±  4  27  ±  5  27  ±  4  <  0.0001
Diabetes 57  (25) 40  (32) 123  (23) 145  (30)  0.056
Dyslipidaemia 121  (54) 81  (64) 271  (51) 331  (67) <  0.0001
Current  smoker 28  (13) 15  (12) 210  (39) 149  (30) <  0.0001
Hypertension  146  (65)  98  (78)  280  (53)  272  (55)  <  0.0001
Hx  of  CAD  16  (7)  17  (13)  91  (17)  110  (22)  <  0.0001
Prior  MI  42  (19)  27  (21)  86  (16)  124  (25)  0.004
Prior  PCI  44  (20)  57  (45)  78  (15)  182  (37)  <  0.0001
Prior  CABG  22  (10)  11  (9)  33  (6)  40  (8)  0.325
Prior  stroke 25  (11)  7  (6)  32  (6)  16  (3)  0.0005
Creatinine  157  ±  137  162  ±  141  78  ±  18  78  ±  17  <  0.0001
CrCl  42  ±  13  42  ±  14  98  ±  32  100  ±  31  <  0.0001
Dialysis  22  (10)  16  (15)  —  —  —
ACS  67  (30)  50  (41)  151  (29)  174  (36)  0.010
AMI  59  (27)  1  (1)  189  (36)  37  (8)  <  0.0001
Cardiogenic  shock  25  (11)  1  (8)  18  (3)  1  (0)  <  0.0001
Out-of-hospital  cardiac  arrest  9  (4)  1  (1)  9  (2)  1  (0)  0.001
Radial  access  169  (82)  90  (81)  425  (88)  403  (90)  0.009
Multivessel  disease  143  (64)  72  (57)  253  (48)  297  (61)  <  0.0001
LM  19  (8)  7  (6)  14  (3)  21  (4)  0.004
LAD  163  (73)  82  (65)  318  (59)  337  (68)  0.001
Circ  102  (46)  54  (43)  214  (40)  219  (45)  0.410
RCA  127  (57)  67  (53)  289  (54)  248  (50)  0.417
Graft  61  (27)  27  (21)  95  (18)  121  (25)  0.011
Number  of  stents/patient  1.6  ±  0.9  1.7  ±  0.9  1.5  ±  0.8  1.7  ±  1.0  0.002
Total  stent  length/patient  25  ±  18  27  ±  17  23  ±  14  28  ±  19  <  0.0001
Average  stent  diameter/patient  2.9  ±  0.4  2.7  ±  0.4  3.0  ±  1.0  2.8  ±  0.8  0.006
Cypher© —  38  (30)  —  174  (35)  0.273
Taxus© — 47  (37)  —  174  (35)  0.686
Endeavor© — 46  (37) — 201  (41)  0.375
Other  DES — 12  (10)  —  30  (6)  0.173
Data are mean ± standard deviation or number (%). ACS: acute coronary syndrome; AMI: acute myocardial infarction; BMI: body mass
index; BMS: bare metal stent; CABG: coronary artery bypass surgery; Circ: circumﬂex artery; CrCl: creatinine clearance; CRF: chronic
renal failure; DES: drug-eluting stent; Hx of CAD: family history of coronary artery disease; LAD: left anterior descending artery;
LM: left main; MI: myocardial infarction; PCI: percutaneous coronary intervention; RCA, right coronary artery.
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pCRF-DES  group,  1.3%  (n  =  3)  of  the  CRF-BMS  group  and  0.8%
(n  =  1)  of  the  CRF-DES  group.  In  cases  of  BMS  implantation,
deﬁnite  ST  occurred  within  the  ﬁrst  month  after  PCI  in  72%
(n  =  13).  The  two  DES  thromboses  occurred  after  the  ﬁfth
month.
Chronic  renal  failure  subgroups
Among  CRF  patients,  the  use  of  DES  was  signiﬁcantly  associ-
ated  with  a  lower  rate  of  outcomes,  with  a  trend  for  less  TLR
without  any  increase  in  ST  at  1  year.  Kaplan-Meier  MACE-free
survival  curves  according  to  renal  function  and  stent  type
are  shown  in  Fig.  2.Independent predictors
After  multivariable  analyses  (Table  2)  of  the  entire  cohort,
the  use  of  DES  appeared  to  be  signiﬁcantly  associated  with
s
a
h
whe  absence  of  MACE  (Odds  Ratio  [OR]  0.376,  95%  conﬁ-
ence  interval  [CI]  0.252—0.561)  and  TLR  (OR  0.386,  95%  CI
.242—0.615)  at  1  year.  The  other  independent  predictors  of
ACE  were  cardiogenic  shock,  out-of-hospital  cardiac  arrest
nd  radial  PCI,  with  an  additional  trend  towards  an  excess  of
ACE  in  CRF  patients  (OR  1.483,  95%  CI  0.990—2.221).  Prior
CI  was  independently  correlated  with  TLR.
iscussion
he  main  ﬁnding  of  our  study  is  that  in  the  contemporary
ractice  of  elective  and  urgent  PCI,  the  use  of  DES  in  non-
elected  patients  with  CRF  appears  to  be  as  least  as  effective
nd  safe  as  BMS  at  1  year,  although  these  patients  carry  a
igher  risk  of  restenosis.  DES  is  independently  associated
ith  the  absence  of  MACE  and  TLR.  Patients  with  CRF  do  not
608  
Figure 2. One-year event-free survival according to renal func-
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eion and the type of stent (Kaplan-Meier). BMS: bare metal stent;
RF: chronic renal failure; DES: drug-eluting stent; MACE: major
dverse cardiac events.
ave  any  excess  of  deﬁnite  ST  within  1  year  compared  with
atients  with  normal  renal  function.
It  is  well  established  that  patients  with  CRF  have  a
orse  prognosis  compared  with  patients  with  normal  renal
unction  [1,2,8,9],  a  ﬁnding  that  we  clearly  report  in  our
tudy,  with  a  two-fold  increase  in  MACE  and  a  four-fold
ncrease  in  the  cardiovascular  death  rate  in  cases  of  CRF.
ur  patients  with  CRF  carry  a  higher  risk  of  adverse  events,
ith  more  comorbidities  (older  age,  more  hypertension)  but
lso  more  severe  cardiovascular  disease  (more  cardiogenic
hock  and  out-of-hospital  cardiac  arrest  at  entrance,  with
ore  multivessel  disease).  However,  other  factors  speciﬁc
t
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Table  2 Independent  predictors  of  major  adverse  cardiac  eve
regression).
Variables Odds  Ratio  
Predictors  of  MACEa
Age  1.007  
Family  history  of  CAD  0.683  
Acute  MI  0.866  
Cardiogenic  shock  8.407  
Out-of-hospital  cardiac  arrest  5.283  
CrCl  <  60  mL/minute  1.483  
Radial  access  0.590  
Multivessel  disease  1.364  
DES  0.376  
Number  of  stents  1.119  
Total  stent  length  1.010  
Predictors  of  TLR
Prior  angioplasty  2.074  
DES  0.386  
Number  of  stents  1.277  
Total  stent  length  1.010  
CAD: coronary artery disease; CrCl: creatinine clearance; DES, drug-el
infarction; TLR: target lesion revascularization.
a CV death, non-fatal MI, non-fatal stroke and TLR.O.  Barthelemy  et  al.
o CRF  —– hyperparathyroidism,  hyperhomocysteinaemia,
oagulation  problems,  etc.  —– are  known  to  be  involved  in
his  unfavourable  outcome  [1,2,10].  This  excess  of  events
s  mostly  driven  by  an  excess  of  cardiovascular  death
14.0%  in  CRF  vs  3.4%),  a  ﬁnding  that  has  already  been
idely  reported,  with  non-ischaemia-related  cardiac  death
ccurring  with  high  frequency  [11]. In  our  study,  CRF  was
ssociated  with  adverse  outcomes,  although  not  signiﬁcantly
P  =  0.056)  due  to  a  lack  of  power  and  a  predominant  causal
ffect  of  other  covariables  (such  as  cardiogenic  shock  or
ES)  on  the  prognosis.
Data  on  outcomes  in  patients  with  CRF  undergoing  PCI  are
parse.  Indeed,  CRF  is  usually  an  exclusion  criterion  in  ran-
omized  trials  and  no  dedicated  randomized  study  has  been
one  in  this  setting.  PCI  remains  more  difﬁcult  in  cases  of
RF,  with  poor  long-term  results  [1,12,13]  and  more  peripro-
edural  complications,  especially  at  the  arterial  puncture
ite  [8,14,15].  There  is  growing  evidence  that  radial  access
or  PCI  leads  to  fewer  bleeding  complications  and  a  bet-
er  outcome  [16—18]. In  our  study,  more  than  80%  of  CRF
atients  had  PCI  by  the  radial  approach  and  radial  PCI  was
ound  to  be  an  independent  predictor  of  survival  without
ACE  (OR  0.59).  Although  our  study  cannot  conclude  on  this
ssue,  results  suggest  a  beneﬁt  for  the  systematic  use  of
adial  access  for  PCI,  except  in  patients  with  an  arteriove-
ous  ﬁstula  for  ongoing  dialysis.
PCI  (with  balloon,  BMS  or  DES)  has  never  demonstrated
ny  survival  beneﬁt  in  patients  with  CRF  [1,3,4]. In  sta-
le  patients,  PCI  with  DES  appears  to  have  no  beneﬁcial
ffect  on  hard  events  compared  with  optimal  medical
herapy  alone  [4].  In  fact,  as  previously  suggested,  non-
ardiovascular  deaths  account  widely  for  mortality  in  these
atients  and  PCI  has  no  impact  on  it.  The  lower  cardiovas-
ular  death  and  MACE  rates  we  observed  in  our  study  are
nts  and  target  lesion  revascularization  at  1  year  (logistic
95%  CI  P
0.991—1.022  0.395
0.406—1.148  0.151
0.568—1.321  0.505
3.581—19.734  <  0.0001
1.625—17.182  0.006
0.990—2.221  0.056
0.369—0.945  0.028
0.943—1.973  0.099
0.252—0.561  <  0.0001
0.760—1.647  0.570
0.988—1.031  0.376
1.309—3.286  0.002
0.242—0.615  <  0.0001
0.845—1.938  0.401
0.987—1.033  0.376
uting stent; MACE: major adverse cardiac events; MI: myocardial
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RDES  in  renal  failure  patients  
due  to  the  discrepancy  in  baseline  characteristics.  Patients
treated  with  DES  were  less  likely  to  have  acute  myocar-
dial  infarction  and  other  comorbidities  (bleeding  diasthesis,
planned  surgery,  poor  compliance,  etc.).  Restenosis  remains
a  matter  of  concern  in  patients  with  CRF,  occurring  in  up
to  60%  of  cases,  although  it  does  not  seem  to  lead  to
more  subsequent  revascularization  than  in  the  general  popu-
lation  [19,20].  However,  it  has  been  hypothesized  that
severe  silent  ischaemia  due  to  angiographic  restenosis  may
account  for  this  increased  cardiac  mortality  [1].  Large  ran-
domized  trials  and  pooled  analyses  have  shown  a  dramatic
decrease  in  restenosis  and  subsequent  TLR  rates  in  the  gen-
eral  population  with  DES  versus  BMS.  Whether  or  not  this
ﬁnding  applies  to  CRF  patients  remains  unclear.  Only  small,
often  retrospective  studies  have  been  conducted,  with
controversial  results,  some  reporting  reduced  TLR  and/or
in-stent  restenosis  rates  [21—24], while  others  not  [25—27].
In  our  study  —– one  of  the  largest  to  our  knowledge  —– we
did  not  observe  any  signiﬁcant  reduction  in  the  TLR  rate
after  DES  implantation  in  CRF  patients  (7%  vs  10%  with  BMS;
P  =  0.44).  This  may  be  due  to  a  lack  of  power  and  the  discrep-
ancy  in  baseline  clinical  and  angiographical  characteristics
between  groups  in  this  ‘‘all-comers’’  registry,  with  a  higher
restenosis  risk  proﬁle  in  the  DES  group  (more  prior  PCI,  more
small  stent  diameters;  Table  1).  Indeed,  DES  appears  to  be
independently  associated  with  a  60%  decrease  in  TLR  in  the
entire  cohort.  DES  was  also  found  to  be  independently  asso-
ciated  with  the  absence  of  ischaemic  events  (OR  0.376)  at
1  year,  suggesting  its  additional  value  in  patients  with  CRF.
As  previously  reported,  we  did  not  observe  any  excess  of
deﬁnite  ST  (American  Research  Consortium  deﬁnition)  [7]
with  DES  at  1  year  in  the  CRF  group  compared  with  BMS
[21,23,24].  However,  our  study  was  not  designed  to  assess
whether  or  not  DES  increased  late  ST  rates  in  CRF  patients,
which  remains  a  major  concern  in  this  setting,  with  longer
follow-up  needed  [28,29].  Although  CRF  is  an  independent
predictor  of  ST,  we  did  not  observe  any  excess  of  ST  at  1
year  between  CRF  and  NO  CRF  patients  [30].
Limitations
The  strengths  of  the  present  study  are  the  relative  high
sample  size  in  this  setting,  the  consecutive  and  prospec-
tive  inclusion  and  the  nearly  complete  1-year  follow-up.
However,  several  limitations  inherent  to  registry  data  exist.
This  was  an  observational,  non-controlled,  non-randomized
study.  Some  patients  allocated  to  the  DES  groups  had
concomitant  BMS  implantation  during  the  same  procedure;
however,  this  accounts  for  only  a  few  patients  (n  =  59,  4.2%).
This  was  an  all-comers,  single-centre  registry,  with  stent
type  (especially  DES)  left  to  the  operators’  discretion;  our
results  therefore  reﬂect  ‘‘real  life’’  practice  but  cannot  be
generalized  to  other  practice  and  do  not  compare  a  type
of  DES  with  BMS.  Medication  data,  especially  the  duration
of  dual  antiplatelet  therapy,  were  not  systematically  col-
lected.Conclusion
In  patients  with  CRF,  the  use  of  DES  for  PCI  appears  to  be  at
least  as  effective  as  BMS,  with  no  increase  in  ST  at  1  year.609
owever,  a  larger,  randomized  trial  with  long-term  follow-up
s  needed  in  this  setting.
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